Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA). Preirradiation temozolomide (150 mg/m(2)/day) was given on a 7-day-on/7-day-off schedule for up to six cycles. The primary end point was the response rate during the 6-month, pre-RT chemotherapy. Tumor tissue was analyzed for the presence of chromosomal deletions on 1p and 19q and for MGMT-promoter methylation. Forty-two patients were enrolled; 39 were eligible. The objective response rate was 32% (6% [complete response, CR], 26% [partial response PR]), and the rate of progression during pre-RT chemotherapy was 10%. The worst nonhematological toxicity was grade 4 in three patients (8%). Twenty-two patients completed concurrent chemotherapy and RT. There were no grade 4 nonhematological toxicities during the concurrent chemotherapy and RT. Seventeen of 28 (60.7%) evaluable cases had codeletion of 1p/19q; all 17 were free from progression at 6 months. Sixteen of 20 (80%) evaluable cases had MGMT-promoter methylation; all 16 were free from progression at 6 months. In conclusion, the rate of progression of 10% during pre-RT temozolomide chemotherapy for newly diagnosed AO and MAO compared favorably with prior experience with pre-RT PCV chemotherapy (20% in RTOG 9402). The toxicity of the dose-intense pre-RT regimen used in this study may warrant evaluation of other, less intense dosing strategies. Future studies will need to prospectively stratify patients according to the presence of deletions of chromosomes 1p and 19q.
Vogelbaum
Michael A
MA
Cleveland Clinic, Brain Tumor and NeuroOncology Center, Cleveland, OH 44195, USA. vogelbm@ccf.org
Berkey
Brian
B
Peereboom
David
D
Macdonald
David
D
Giannini
Caterina
C
Suh
John H
JH
Jenkins
Robert
R
Herman
James
J
Brown
Paul
P
Blumenthal
Deborah T
DT
Biggs
Christopher
C
Schultz
Christopher
C
Mehta
Minesh
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001254:Astrocytoma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002872:Chromosome Deletion; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D002888:Chromosomes, Human, Pair 19 / Q000235:genetics; D003131:Combined Modality Therapy; D019175:DNA Methylation; D015254:DNA Modification Methylases / Q000235:genetics; D045643:DNA Repair Enzymes / Q000235:genetics; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000628:therapy*; D009837:Oligodendroglioma / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011379:Prognosis; D011401:Promoter Regions, Genetic; D015996:Survival Rate; D000077204:Temozolomide; D016896:Treatment Outcome; D025521:Tumor Suppressor Proteins / Q000235:genetics; D055815:Young Adult
D000972:Antineoplastic Agents, Phytogenic; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide
Neuro Oncol. 2007 Jul;9(3):314-8
17435180
J Neurosurg. 1985 Dec;63(6):881-9
4056902
J Clin Oncol. 1994 Oct;12(10):2013-21
7931469
J Neurooncol. 2003 Feb;61(3):267-73
12675321
Cancer Treat Rev. 1997 Jan;23(1):35-61
9189180
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
9776413
Neurology. 2001 Jul 24;57(2):340-2
11468326
Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30
11020580
J Clin Oncol. 1990 Jul;8(7):1277-80
2358840
Cancer Res. 2001 Jun 15;61(12):4689-92
11406538
Oncogene. 1999 Jul 15;18(28):4144-52
10435596
Cancer Chemother Rep. 1966 Mar;50(3):163-70
5910392
Lancet Oncol. 2001 Sep;2(9):552-60
11905710
J Neurooncol. 2003 Sep;64(3):271-8
14558604
J Clin Oncol. 2001 May 1;19(9):2449-55
11331324
J Clin Oncol. 2006 Jun 20;24(18):2715-22
16782911
Clin Cancer Res. 2001 Apr;7(4):839-45
11309331
Br J Cancer. 2000 Sep;83(5):588-93
10944597
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Cancer Res. 1998 Oct 1;58(19):4363-7
9766665
J Clin Oncol. 2006 Jun 20;24(18):2707-14
16782910
J Neurosurg. 1996 Oct;85(4):602-7
8814163
J Clin Oncol. 2000 Feb;18(3):636-45
10653879
Cancer Res. 2006 Oct 15;66(20):9852-61
17047046
J Clin Oncol. 2003 Jul 1;21(13):2525-8
12829671